NewsFeed Voices Science Insight Innovation
November, 2025
November 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
Preventing VTE in Cancer, Maintaining Low Bleeding Risk: Reduced-Dose Apixaban
Jul 13, 2025, 17:57

Preventing VTE in Cancer, Maintaining Low Bleeding Risk: Reduced-Dose Apixaban

Mario Balsa, medical oncology resident at Institut Català d’Oncologia, shared an insightful post on X:

” ‘New’ The New England Journal of Medicine (NEJM) study in 1,766 patients with cancer-associated VTE:

  • Reduced-dose apixaban (2.5mg BID) vs full dose (5mg BID)
  • VTE recurrence: 2.1% vs 2.8%
  • Clinically relevant bleeding: 12.1% vs 15.6%

Same protection, less bleeding. Sometimes, less really is more!”

Effects of reduced dose of an oral anticoagulant on thromboembolic events and bleeding are discussed in the new study ”Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism” published by Isabelle Mahé et al. in the New England Journal of Medicine (NEJM).

In patients with active cancer and venous thromboembolism, extended treatment with reduced-dose apixaban was as effective as the full dose in preventing recurrent events.

Moreover, dose reduction resulted in fewer bleeding complications.

This supports reduced-dose apixaban as a safer alternative for long-term anticoagulation in this population.

Never miss the scientific advancements in the World of Hematology, read Hemostasis Today.

cancer induced venous thromboembolism Health Hematology Hemostasis Today Isabelle Mahé Medicine NEJM Reduced-Dose Apixaban venous thromboembolism
NewsFeed